endpoint and THREAD DCT Solution Partnership
endpoint Clinical and THREAD have announced their partnership to offer sponsors and sites a solution that aims to simplify decentralized trials (DCT) operations and reduce research study timelines.
Through this partnership, endpoint Clinical and THREAD will provide two-way integration for eConsent, screening, and randomization, supporting automation of underlying workflows across the two platforms. The interfacing of systems has a particular impact on sites, as they do not need to duplicate data entry. In addition, this integrated approach aims to simplify operations such as subject creation, screening, assessments, randomization (including dispensing), and subject treatment visits. Two-way communication between the platforms enables data-driven feedback that can inform strategies for patient recruitment, supply procurement, clinical operations, and data management.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
